Leading the
global fight
against cancer
 

Union for International Cancer ControlUICC

“We unite and support the cancer community to reduce the global cancer burden, to promote greater equity, and to ensure that cancer control continues to be a priority in the world health and development agenda.”

 
Our main missions
icon_convening-orange.png
Convening

Convening the global cancer control community through our keystone events

icon_capacity-building-orange.png
Capacity building

Developing capacity building initiatives to strengthen the cancer community

icon_advocacy-orange.png
Advocacy

Promoting cancer in the global health and development agendas

Our key platforms
icon_wcd-blue.png
World Cancer Day 2020 - 4 Feb

162

days

Latest news and updates
Our news and updates
Palliafamilli
22 August 2019

DRC: Palliative Care in a culture that avoids the word “death”

Palliafamilli is a Non-Governmental Organisation of Congolese law, based in Kinshasa, Democratic Republic of Congo. Palliafamilli specialises in Palliative Care and supports patients and their families at home. During a visit to the UICC offices in Geneva, Anselme Mubeneshayi Kanaga, President of the Palliafamilli Association talked to us about his challenges and success stories.

 

Cross_boarder_Cancer_Control_china
15 August 2019

The power of cross-border collaboration for cancer control

Over 20,000 delegates from the Asian region will come together this Friday 16 August for the 2019 annual Chinese Conference on Oncology in Chongqing, China. This year’s theme, ‘Oncology Prevention and Control Winning in Integration’ will explore the value of collaboration in cancer control.

Omanis talking.jpg
9 August 2019

World Cancer Congress 2020 in Oman: How will you participate?

Our preparations for the next World Cancer Congress on 20-22 October 2020 in Muscat, Oman are already well underway. We are expecting over 3,500 participants representing cancer research institutions, civil society organisations, healthcare services, hospitals, governments, international agencies, patient group organisations, universities and many more.

Red meat linked to breast cancer increase
5 August 2019

Study finds a possible link between Meat Consumption and Risk of Breast Cancer

A study published today in the International Journal of Cancer has examined the link between meat consumption and cooking practices. The study found that red meat consumption increases the risk of breast cancer. Dr Giota Mitrou, Director of Research at World Cancer Research Fund International (WCRF) comments on the study, cancer and nutrition more broadly.

Spotlight on
world-map-essential-medicines
12 July 2019

12 new cancer medicines added to the WHO List of Essential Medicines

The World Health Organization (WHO) published an updated version of its Essential Medicines List (EML). UICC welcomes the strong focus on cancer with twelve new cancer medicines added.

Khazakhstan.jpeg
10 July 2019

World Cancer Leaders’ Summit: Destination Kazakhstan

Every year, the Union for International Cancer Control (UICC) brings together key decision makers from around the world to facilitate debates about emerging issues related to cancer control.

From our network
News feed
23 August 2019

Global Retinoblastoma Treatment Market has been thoroughly analyzed in the report for an inclusive understanding. The report includes...

Source: FOX 40 WICZ TV
21 August 2019

Tratamiento del sarcoma de tejido blando infantil (PDQ®)–Versión para profesionales de salud - Instituto Nacional del Cáncer Tratamiento...

21 August 2019

Artikel einzeln kaufen Lizenzen und Reprints Alle Artikel dieser Rubrik Merkel-Zell-Karzinome (MCC) sind hochmaligne neuroendokrine Tumore...

19 August 2019

Abstract Introduction Differentiated thyroid cancer (DTC) is the most common of endocrine cancers. Many studies have focused on...

Source: Plos One
16 August 2019

O-glycosylation of neuropilin-1 is involved in cancer migration and invasion. Here, the authors show that defects in N-glycosylation of two...

Source: Nature
Member spotlight
CANSEARCH Foundation logo.png
CANSEARCH Foundation

The CANSEARCH Foundation, created in 2011 by Prof. Marc Ansari, head of the Paediatric Oncology Haematology Unit at Geneva University Hospitals (HUG), supports research projects on childhood cancers and blood diseases, and seeks to improve the understanding and treatment of these diseases. A research platform in this specific issue was set up in Geneva, with the collaboration of the HUG and the Faculty of Medicine of the Geneva University. Its research focuses on different types of cancer in children: leukaemia, neuroblastoma, liver cancer and brain tumours, as well as stem cell transplants and side effects. In Geneva, it offers a medicine of excellence, personalised and highly specialised. The use of individualised therapies based on genetics reduces the toxicity of drugs and thus side effects, improving survival and quality of life in the long term.

Our Partners
Amgen logo
Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Astellas
Astellas

The Astellas Group aims to become a R&D-driven global pharmaceutical company contributing to people’s health. Astellas’s business philosophy has three elements — raison d'être, mission and beliefs. This business philosophy expresses the company’s aim to contribute to the health of people around the world through the provision of highly effective and trustworthy pharmaceuticals, while continuously increasing the Company's enterprise value.

Bristol-Myers_Squibb_logo.png
Bristol-Myers Squibb (BMS)

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

CACA logo.jpg
China Anti-Cancer Association (CACA)

Established in 1984, the China Anti-Cancer Association (CACA) is a non-government and non-profit organisation with a mission to unite people involved in all branches of oncology with a shared interest in fighting cancer. CACA is dedicated to improving cancer control in China through increasing the survival rates, and decreasing the incidence and mortality rates of cancer. CACA plays an important role in promoting academic exchange, organising public education, establishing collaboration with international cancer societies, and providing data and advice to the Chinese government for making strategies and policies on cancer control. The branches consist of 45 professional societies, 47 full membership organisations, and 30 local anti-cancer associations with a total membership exceeding 47,000.

CUBEBIO_logo.png
CUBEBIO

CUBEBIO is a biomedical company, headquartered in Seoul, South Korea, dedicated to researching and developing cancer diagnostic biomarkers and in vitro diagnostics. The company also possesses more than 30 patents in relation to cancer diagnosis. Since its establishment, CUBEBIO commits itself to the continuous research and development for global health improvements by detecting cancer early through self-diagnosis by means of urine as a specimen. CUBEBIO’s urine-based self-diagnostic technology enables anyone to check their cancer status fast, accurately, economically, and frequently, thereby making early screening possible and, in the case of cancer patients, allowing them to monitor their cancer for progression or recurrence.

CUBEBIO aims to enter world markets by fostering close working relations with cancer societies, foundations, and research centers in each and every country. By doing so, CUBEBIO works towards creating a new culture where complex cancer diagnostic procedure becomes simpler and more accessible by self-diagnosis, regardless of time and place, and thus emerges as a new global leader in the healthcare industry.

DKG
DKG Krebsgesellschaft

The German Cancer Society (DKG) is the largest scientific and specialist oncology company in Germany with headquarters in Berlin. They are engaged in cancer care on the basis of evidence-based medicine, interdisciplinary and consequent quality standards. In total, DKG has about 7600 members, organised in 24 working groups, 16 regional cancer societies and 34 sponsors from research-based pharmaceutical industries, scientific publishers and health insurances. Since cancers need to be cross-treated and researched, their members are not only medical doctors of all sections, but also basic researchers, medical technical assistants, nurses, psychologists and other professionals who work on cancer.

DKG specialises in certification of oncological care institutions, development of clinical practice guidelines, coordination of guidelines in the framework of the German Guideline Program of Oncology (GGPO), development and transfer of oncological knowledge, and improvement of information given to patients.

Elekta logo
Elekta

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Their advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology.

Their treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm

Fondation Philantropia
Fondation Philantropia

An umbrella foundation associated with the bank Lombard Odier and a registered charity, Fondation Philanthropia has been helping its donors bring their philanthropic initiatives to fruition in all areas of social responsibility since 2008. It provides philanthropic expertise and support to those who wish to develop a philanthropic project in line with their background, desires and ambitions. The Foundation offers its donors a legal, financial and philanthropic framework for made-to-measure projects.

The Foundation now operates more than 20 personal funds and has received over 115 million Swiss francs in donations, of which over a third has already been distributed or committed. Its donors have been highly committed to the fight against cancer, with over 15 million spent on the cause.

Friends of Cancer Patients (FOCP)
Friends of Cancer Patients (FOCP)

Friends of Cancer Patients UAE (FoCP UAE) charity is a non-profit organisation, founded in September 1999 under the directives and patronage of Her Highness Sheikha Jawaher Bint Mohammed Al Qasimi, Wife of the Ruler of Sharjah, United Arab Emirates (UAE).

FoCP UAE provides a broad spectrum of support for its patients including financial support, which entails covering treatment expenses for chemotherapy, radiation and other needed medications, in addition to expenses for investigative and surgical procedures including bone marrow transplants and prosthetic limbs. FoCP UAE provides transportation and food allowance for underprivileged cancer patients and facilitates sending patients abroad for specialised treatment. FoCP UAE also provides moral support, offering cancer patients and their families psychological consultations and Hajj and Umrah services.

ICONGROUP__CMYK_Logo.png
ICON Group

Icon Group is a leading provider of cancer care across Australasia. Icon believes in bringing the best cancer treatment possible, to as many people as possible, as close to home as possible. They do this through leveraging the latest technology, collaborating with like-minded partners and investing in outstanding people.

Johnson & Johnson logo
Johnson & Johnson

Caring for the world one person at a time inspires and unites the people of Johnson & Johnson. They embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Their approximately 126,400 employees at more than 230 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

For 130 years, Johnson & Johnson has been committed to improving the health of individuals, families and communities around the world, including the most vulnerable populations. Today, their vibrant, entrepreneurial and committed employees bring business acumen and their collaborative spirit to help solve some of the most complex global health problems. By harnessing their collective breadth and scale, and their employees’ passion and purpose, Johnson & Johnson strives to advance health care and positively impact the lives of all people.

Kazior Logo
Kazakh Research Institute of Oncology & Radiology (KazIOR)

Kazakh Research Institute of Oncology & Radiology is the equivalent of National Cancer Institute in Kazakhstan. It's responsible for all cancer control programs in Kazakhstan. Hospital is providing multidisciplinary approach to cancer treatment, education and training. Our Institute is making cancer policy in Kazakhstan. Two nation-wide screening programs for breast and cervical cancer were launched in 2008 with the support of Ministry of Health.
At present time we are working on development screening programs for colorectal, prostate & gastric cancer.

MERCK_LOGO_Blue_RGB.png
Merck KGaA

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.  Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the “Merck” name and brand except in the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

MSD be well
MSD (Merck & Co)

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases.  MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.

National Cancer Institute (NCI)
National Cancer Institute (NCI)

The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Novartis logo
Novartis Oncology

Novartis Oncology is a global leader in transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help meet patient needs and have one of the strongest, most productive pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets.

Pfizer
Pfizer

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.

Roche logo
Roche

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide.

Swiss Cancer League
Swiss Cancer League

The Swiss Cancer League is a national, charitable, private organisation, founded in 1910. It is the Berne-based headquarter of an association of 19 regional cancer leagues. The Swiss Cancer League covers all aspects of cancer, with the aim of ensuring that fewer people develop cancer, fewer people suffer and die from the consequences of cancer and more people can be treated successfully. The organisation supports innovative cancer research projects, increases public awareness of prevention measures and is committed to early diagnosis and treatment. One of its first concerns is to ensure high-quality advice and psychological support for all cancer patients and survivors and their caretakers. The Swiss Cancer League also supports other cancer control organisations in low income countries.

Takeda Oncology logo
Takeda Oncology

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries.

Tata Trusts
Tata Trusts

Tata Trusts are amongst India's oldest, non-sectarian philanthropic organisations. The Trusts own two-third of the stock holding of Tata Sons, the apex company of the Tata group of companies. The wealth that accrues from this asset supports an assortment of causes, institutions and individuals in a wide variety of areas. In this manner, the profits that the Tata companies earn go back many times over to the communities they operate in. These funds have been deployed towards a whole range of community development programmes across the country, for over a 100 years now.

UICC Japan
UICC Japan

The Japan National Committee for UICC is a group of Japanese organisations that are members of the Union for International Cancer Control (UICC), gathered to support the UICC to strive to realise the World Cancer Declaration. Currently UICC-Japan is composed of 29 full Japanese UICC members, including major cancer specialists in Japan, cancer centres, research institutes, research funds, hospitals and cancer associations.

Varian
Varian

Varian Medical Systems’ mission is to focus energy on saving lives. To meet this challenge, they equip the world with new tools for fighting cancer. Since the 1950s they have been producing tools that harness the power of X-ray energy to benefit humankind. Varian’s history is one of pioneering developments in the fields of radiotherapy, radiosurgery, X-ray tube technology, digital image detectors, cargo screening, and non-destructive testing. Today, they have a robust product portfolio and long-standing relationships with many of the world’s leading clinicians. As Varian continues to grow, their staff of over 6,500 people in 70 sales and support offices around the globe is developing innovative, cost-effective solutions that help make the world a healthier place.

WCRF
World Cancer Research Fund International (WCRF)

World Cancer Research Fund International is the world’s leading authority on cancer prevention research related to diet, weight and physical activity. Their vision is to live in a world where no one develops a preventable cancer. On behalf of the cancer prevention charities in the World Cancer Research Fund network, WCRF commissions research from leading institutions around the world into the effects of diet, nutrition, body fatness, physical activity on cancer and cancer survival. This research aims to fill the current gaps in scientific knowledge.

Give us
your support
 

Are you organising a cancer-related event and would like to feature it in our events section?

 

Are you interested in joining a dynamic network of over 1,000 members?

 

Would you like to support the work of UICC and its member organisations?